What's new? Log in Free sign up

Relay Therapeutics (RLAY)

Company Profile

Company profile

Ticker

RLAY

Exchange

Website

www.relaytx.com

CEO

Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • bluebird bio • Acorda Therapeutics ...

Former names

New PennyMac Financial Services, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Relay Securities Corporation • Relay ML Discovery, LLC ...

RLAY stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Submission of Matters to a Vote of Security Holders

Entry into a Material Definitive Agreement

Quarterly report

5 May 25

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

23 Apr 25

Registration of securities for employees

Latest ownership filings

View all

Claire Mazumdar

Claire Mazumdar

DOUGLAS S INGRAM

Sekar Kathiresan

COMMODORE CAPITAL LP

Financial summary

Financial statements Chart RLAY financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	95.66 mm	95.66 mm	95.66 mm	95.66 mm	95.66 mm	95.66 mm
Cash burn (monthly)	10.25 mm	4.99 mm	28.29 mm	30.58 mm	24.40 mm	22.67 mm
Cash used (since last report)	28.70 mm	13.98 mm	79.23 mm	85.65 mm	68.35 mm	63.48 mm
Cash remaining	66.96 mm	81.68 mm	16.43 mm	10.01 mm	27.31 mm	32.18 mm
Runway (months of cash)	6.5	16.4	0.6	0.3	1.1	1.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

RLAY institutional ownership history Ownership history

95.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	199	193	+3.1%
Opened positions	44	46	-4.3%
Closed positions	38	31	+22.6%
Increased positions	87	70	+24.3%
Reduced positions	35	46	-23.9%

13F shares	Current	Prev Q	Change
Total value	651.64 bn	1.06 tn	-38.7%
Total shares	163.97 mm	157.45 mm	+4.1%
Total puts	26.80 k	40.00 k	-33.0%
Total calls	100.30 k	207.30 k	-51.6%
Total put/call ratio	0.3	0.2	+38.5%

Largest owners	Shares	Value	Change
SB Investment Advisers	27.90 mm	$114.97 bn	0.0%
Vanguard	15.03 mm	$61.92 bn	+3.9%
BlackRock	14.67 mm	$60.46 bn	+25.0%
Casdin Capital	8.95 mm	$36.87 bn	-3.3%
Tang Capital Management	8.07 mm	$33.24 bn	+126.1%
BLVGF Bellevue	7.38 mm	$30.39 bn	+0.0%
Norges Bank	5.78 mm	$23.82 bn	NEW
STT State Street	5.28 mm	$21.75 bn	+22.8%
JPM JPMorgan Chase & Co.	4.98 mm	$20.51 bn	-9.8%
Nextech Invest	3.85 mm	$15.85 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	5.78 mm	+5.78 mm	NEW
Tang Capital Management	8.07 mm	+4.50 mm	+126.1%
Braidwell	0.00	-3.50 mm	EXIT
BlackRock	14.67 mm	+2.93 mm	+25.0%
Citadel Advisors	686.88 k	-2.22 mm	-76.4%
T. Rowe Price	3.32 mm	-1.96 mm	-37.1%
EcoR1 Capital	641.43 k	-1.86 mm	-74.3%
Boxer Capital	0.00	-1.82 mm	EXIT
First Light Asset Management	0.00	-1.54 mm	EXIT
Millennium Management	2.57 mm	+1.51 mm	+142.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RLAY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Jun 25	Claire Mazumdar	Stock Option Common Stock	Grant	Acquire A	No	No	3.36	421,241	1.42 mm	421,241
6 Jun 25	Jami Rubin	Stock Option Common Stock	Grant	Acquire A	No	No	3.36	136,681	459.25 k	136,681
6 Jun 25	Sekar Kathiresan	Stock Option Common Stock	Grant	Acquire A	No	No	3.36	136,681	459.25 k	136,681
6 Jun 25	Mark Murcko	Stock Option Common Stock	Grant	Acquire A	No	No	3.36	136,681	459.25 k	136,681

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Relay Therapeutics Says Updated Interim Clinical Data For RLY-2608 Remain Consistent, Showing 10.3-Month Median PFS Overall And 11.0-Month Median PFS In 2L Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancerData continue to support planned initiation of

Guggenheim Maintains Buy on Relay Therapeutics, Lowers Price Target to $10

Guggenheim analyst Michael Schmidt maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $30 to $10.

Relay Therapeutics Q1 EPS $(0.46) Beats $(0.48) Estimate, Sales $7.68M Beat $10.00K Estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.48) by 4.17 percent. This is a 25.81 percent increase over losses of $(0.62) per share from

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wells Fargo Initiates Coverage On Relay Therapeutics with Equal-Weight Rating, Announces Price Target of $4

Press releases

From Benzinga Pro

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation

Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.